Provided by Tiger Fintech (Singapore) Pte. Ltd.

PRESCIENT THERAPEUTICS LTD

0.047
0.000
Volume:3.64M
Turnover:171.32K
Market Cap:37.85M
PE:-5.36
High:0.049
Open:0.047
Low:0.044
Close:0.047
Loading ...

Company Profile

Company Name:
PRESCIENT THERAPEUTICS LTD
Exchange:
ASX
Establishment Date:
1986
Employees:
3
Office Location:
Suite 2,Level 11,385 Bourke Street,Melbourne,Victoria,Australia
Zip Code:
3000
Fax:
61 3 9077 9233
Introduction:
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company's lead drug candidate is PTX-200, which is in Phase II clinical trial for negative breast cancer, as well as Phase IB clinical trial in relapsed and refractory ovarian cancer and acute leukemia; and PTX-100, a treatment that has completed Phase I clinical trial for solid tumors. It has a collaboration agreement with Carina Biotech to develop next generation cellular therapies. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited is based in South Melbourne, Australia.